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a b s t r a c t
Adenosine deaminases that act on RNA (ADARs) have been reported to be functional on various viruses.
ADAR1 may exhibit antiviral or proviral activity depending on the type of virus. Human immunodeﬁ-
ciency virus (HIV)-1 is the most well-studied lentivirus with respect to its interaction with ADAR1, and
variable results have been reported. In this study, we demonstrated that equine ADAR1 (eADAR1) was a
positive regulator of equine infectious anemia virus (EIAV), another lentivirus of the Retroviridae family.
First, eADAR1 signiﬁcantly promoted EIAV replication, and the enhancement of viral protein expression
was associated with the long terminal repeat (LTR) and Rev response element (RRE) regions. Second, the
RNA binding domain 1 of eADAR1 was essential only for enhancing LTR-mediated gene expression. Third,
in contrast with APOBEC proteins, which have been shown to reduce lentiviral infectivity, eADAR1
increased the EIAV infectivity. This study indicated that eADAR1 was proviral rather than antiviral
for EIAV.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Adenosine deaminases that act on RNA (ADARs) are RNA-
editing enzymes that recognize double stranded RNA (dsRNA) and
mediate the conversion of adenosine (A) to inosine (I) (Bass, 2002;
Nishikura, 2010; Samuel, 2011). The base-pairing properties of inosine
are different from those of adenosine, and thus, A-to-I editing alters
RNA structure, coding potential and splicing patterns (Samuel, 2011).
Recently, ADARs have been shown to edit the genomes of many
viruses, including the measles virus (Cattaneo et al., 1988), human
parainﬂuenza virus (Murphy et al., 1991), respiratory syncytial virus
(Martinez et al., 1997), inﬂuenza virus (Gutierrez et al., 2013; Suspene
et al., 2011), lymphocytic choriomeningitis virus (Zahn et al., 2007),
human T-cell leukemia virus type 2 and simian T-cell leukemia virus
type 3 (Ko et al., 2012), during viral infection. Notably, ADAR1 can
either promote or inhibit viral replication. For certain viruses, such
as human immunodeﬁciency virus (HIV)-1, vesicular stomatitis virus
(VSV) and hepatitis D virus (HDV) (Casey, 2006; Clerzius et al., 2009;
Doria et al., 2011; Nie et al., 2007; Phuphuakrat et al., 2008), ADAR1
is proviral. However, ADAR1 inhibits the replication of other viruses,
such as hepatitis C virus (Taylor et al., 2005) and the measles virus
(Ward et al., 2011). For HIV-1 and VSV, ADAR1 enhances viral replica-
tion by inhibition of dsRNA activated protein kinase (PKR), which
suppresses viruses replication by shutting off the expression of viral
proteins (Clerzius et al., 2009; Gelinas et al., 2011; Li et al., 2010; Nie
et al., 2007). HDV replication requires ADAR1 editing activity for
producing its large antigen by catalyzing stop codon UAG into
tryptophan codon UGG in HDV mRNA (Casey, 2006). However, in
general, virus replication inhibition was suspected due to ADAR1
massive editing activity (Ko et al., 2012; Suspene et al., 2011; Taylor
et al., 2005).
Similar to HIV-1, equine infectious anemia virus (EIAV) is a
member of the Lentivirus genus of the Retroviridae family. EIAV
causes a persistent infection characterized by recurring febrile
episodes associated with viremia, fever, thrombocytopenia and
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wasting symptoms in equids (Leroux et al., 2004). However, with
respect to HIV-1 studies, different results have been found
regarding the interaction of ADAR1 and HIV-1. Many groups have
found that ADAR1 positively regulates HIV-1 (Clerzius et al., 2009;
Doria et al., 2011; Phuphuakrat et al., 2008), and one group has
reported that ADAR1 inhibits HIV-1 replication (Biswas et al.,
2012). Consequently, investigating the interaction between EIAV
and ADAR1 will increase our understanding of the ADAR1 function
in lentiviruses.
Results
Equine ADAR1 positively regulated EIAV, HIV-1 and SIV replication
To investigate the role of eADAR1 in EIAV replication, HEK293T
cells were co-transfected with the eADAR1 expression plasmid and
EIAV-CMV-3-8, an EIAV proviral clone derived from the live attenu-
ated vaccine strain EIAVFDDV13 (Tang et al., 2014;Wang et al., 2011). The
amounts of EIAV-CMV-3-8 in the cell lysates and culture supernatants
were estimated by measuring the levels of EIAV Gag (p55) and capsid
(CA or p26, cleaved from p55) protein by western blot at 48 h post
transfection (hpt). As shown in Fig. 1A, the levels of the viral capsid
protein and its precursor in the cell lysate were signiﬁcantly greater in
cells co-transfected with ADAR1, and this increase was dose depen-
dent. Furthermore, the levels of p26 in viral particles released into the
culture supernatant also increased substantially in response to ADAR1
overexpression.
These results indicate that EIAV production increased in response
to eADAR1 overexpression. To determine whether eADAR1 promotes
the replication of viruses other than EIAV, we examined the effects of
eADAR1 overexpression on human lentivirus HIV-1 and simian
lentivirus simian immunodeﬁciency virus (SIV) replication. HEK293T
cells were co-transfected with the plasmids expressing either HIV-
1NL4–3 or SIVmac239, together with increasing doses of the eADAR1
expression vector. The levels of viral Gag protein in the cell lysates and
culture supernatants were examined by western blot. As shown in
Fig. 1B and C, the amounts of both HIV-1 and SIV structural proteins in
both cell lysates and supernatants increased with increasing levels of
eADAR1 expression, indicating that eADAR1 activity upregulates the
replication of multiple lentiviral species.
To examine whether endogenous eADAR1 also promotes EIAV
replication, we targeted ADAR1 in eMDMs with speciﬁc siRNAs,
resulting in efﬁcient knockdown of ADAR1 expression at the mRNA
level (Fig. 1D). Twelve hours post siRNA transfection, 2.5 ng of
EIAVDLV34 (as determined by RT activity) was used to infect the cells
in 96-well plates. Viruses were collected from the supernatant and
titrated by measuring the viral RT activity 72 h post infection (hpi).
Our results show that the knockdown of eADAR1 signiﬁcantly
inhibited the production of EIAV (Fig. 1E) compared with the mock
and non-speciﬁc siRNA controls.
Equine ADAR-1-mediated promotion of EIAV expression is associated
with the LTR and RRE regions
ADAR1 binding on RNA depends on the double-stranded RNA
secondary structure (Bass, 2002; Nishikura, 2010; Samuel, 2011). It is
logical to investigate whether this structure is also essential for the
activity of ADAR1 in promoting EIAV expression. In the single-stranded
positive-sense RNA genome of EIAV, two regions contain such
secondary structures: the long terminal repeat (LTR) and the Rev
response element (RRE) regions in the envelope (env) gene. We ﬁrst
investigated whether the LTR region is necessary for eADAR1-
mediated promotion of EIAV expression. The EIAV LTR region functions
as the promoter for EIAV transcription. We subcloned this fragment
into a pGL3-Basic plasmid to measure the activity of LTR by detecting
downstream luciferase activity. To determine whether eADAR1 affects
EIAV LTR-mediated gene expression, fetal equine dermal (FED) cells
were co-transfected with the LTR-luciferase plasmid and either the
eADAR1 expression plasmid or an empty vector. The results, presented
in Fig. 2A, showed that eADAR1 overexpression increased luciferase
activity by a factor of 4.22 compared with the vector control, indicating
that eADAR1 expression enhances LTR-mediated gene expression. The
result indicated that the eADAR1-mediated increase in luciferase
expression correlated with the LTR region.
Next, we examined the role of the RRE region in eADAR1-
promoting activity. We constructed two different expression
plasmids for EIAV env expression that expressed either the wild-
type env (pEIAV-Env) with a functional RRE region or a codon-
optimized env (pEIAV-Env-opti), in which the RRE secondary
structure was destroyed. HEK293T cells were then transfected
with one of these plasmids and the ADAR1 expression vector. The
level of viral envelope protein (Env) expressed in these cells was
examined by western blot. As presented in Fig. 2B and C, eADAR1
overexpression increased the Env expression in cells expressing
the wild-type env gene, but not in cells expressing the env gene
that lacked the RRE secondary structure. This ﬁnding indicates that
an intact RRE secondary structure is required for eADAR1-mediated
promotion of Env expression.
We also investigated the effects of ADAR1 on two non-
structural EIAV proteins: transactivator of transcription (Tat) and
regulator of virion expression (Rev), which regulate viral replica-
tion (Dorn and Derse, 1988; Leroux et al., 2004; Martarano et al.,
1994). EIAV Tat or Rev was expressed in HEK293T cells, together
with increasing doses of eADAR1. The levels of Tat and Rev protein
in cell lysates were examined by western blot. We did not observe
any noticeable changes in the densities of the relevant bands
(Fig. 2D and E), indicating that eADAR1 overexpression did not
affect the expression of these regulatory proteins. The Tat coding
region does not encode a double-stranded RNA secondary struc-
ture, and Rev contains only a partial RRE sequence (Lee et al.,
2008). Our results further conﬁrm that an intact RRE is essential
for eADAR1 to promote viral protein expression.
The eADAR1 RNA binding domain 1 was required to promote EIAV
expression
When compared with the sequence of human ADAR1, eADAR1
was predicted to consist of three functional regions. The N-
terminal region contains two copies of a Z-DNA binding domain,
Zα and Zβ. The central region of eADAR1 contains a double-
stranded RNA-binding domain, designated as dsRBD or R. The
C-terminal region of eADAR1 is the deaminase catalytic domain
(Cat). As shown in Fig. 1A and 2A, eADAR1 enhanced EIAV protein
expression and was associated with the LTR region. To determine
which domain or domains of eADAR1 were required to promote
EIAV gene expression, we generated constructs in which the DNA
binding domain, the RNA binding domain or the Cat domain of
eADAR1 was deleted (Fig. 3A). We then examined the ability of
these deletion mutants to promote LTR-mediated gene expression
by co-transfecting plasmids expressing the eADAR1 deletion
mutants and the LTR-luciferase reporter plasmid into FED cells
and measuring the resulting luciferase activity. Western blot
analysis showed that these eADAR1 mutants were expressed at
the predicted molecular weights (Fig. 3B). As shown in Fig. 3C,
deletion of the RNA-binding domain, but not the DNA-binding
domain or Cat domain, signiﬁcantly decreased the luciferase
activity, indicating that RNA binding was required for ADAR1 up-
regulation of EIAV protein expression.
We further examined the roles of these three domains sepa-
rately with respect to the activity of a LTR-luciferase reporter
(Fig. 3D and E). Only the RNA-binding region was sufﬁcient to
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positively regulate LTR-luciferase expression (Fig. 3F). Because the
RNA-binding region contains three RNA-binding domains (RI, RII
and RIII), each of these domains was further either deleted or
expressed separately to investigate its role in enhancing LTR-
luciferase expression (Fig. 4A, B and D, E). To our surprise, deleting
RI alone eliminated the enhancement of LTR-luciferase activity by
eADAR1 (Fig. 4C), and expression of only RI was sufﬁcient to
enhance the LTR activity to an extent similar to that observed with
intact eADAR1 (Figs. 4F and 3F). These results indicate that the RI
domain is essential for the eADAR1-mediated promotion of LTR-
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Fig. 1. Equine ADAR1 enhances lentivirus production. (A) Overexpression of eADAR1 increased EIAV production, as observed both in cell lysates and culture supernatants. An
infectious EIAV clone, EIAV-CMV3-8 (50 ng of DNA), was transfected into HEK293T cells along with different amounts of the eADAR1 expression vector (0, 0.5, 1 or 2 μg).
Virus production was quantiﬁed by western blotting using an anti-EIAV p26 monoclonal antibody. EIAV p26 enhanced by eADAR1 was quantiﬁed by densitometry scanning
of western blot images of three independent experiments. *Po0.05. (B) Overexpression of eADAR1 increased HIV-1 production. HEK293T cells were transfected with 500 ng
of HIV-1NL4–3 proviral DNA along with different amounts of the eADAR1 expression vector (0, 0.5, 1 or 2 μg). The levels of HIV-1NL4–3 and eADAR1 expression were detected
by western blot. HIV-1 p24 expression enhanced by ADAR1 was quantiﬁed by densitometry scanning of western blot images of three independent experiments. *Po0.05.
(C) Overexpression of eADAR1 increased SIV production. HEK293T cells were transfected with 500 ng of SIVmac239 proviral DNA along with different amounts of the ADAR1
expression vector (0, 0.5, 1 or 2 μg). The levels of SIVmac239 and eADAR1 expression were detected by western blot. SIV p27 expression enhanced by ADAR1 was quantiﬁed by
densitometry scanning of western blot images of three independent experiments. *Po0.05. (D) eADAR1 transcription was knocked down by siRNA. eMDMs were transfected
with either 50 nM of one of three ADAR1-speciﬁc siRNA species (siADAR11-3) or 50 nM of a scrambled siRNA control (siScr) or mock transfected (Mock). At 24 hpt, eADAR1
(upper panel) and β-actin (lower panel) mRNA levels were quantiﬁed by semi-quantitative PCR. (E) Knockdown of eADAR1 transcription increased EIAV replication in equine
monocyte-derived macrophages (eMDMs). eMDMs were transfected with 50 nM siADAR1 or siScr for 12 h and then infected with 2.5 ng of EIAVDLV34. The viral titers in the
supernatants were assessed at 72 hpi by measuring the RT activity. P values o0.05 were considered statistically signiﬁcant. The images shown in A, B and C are
representative of three independent experiments. *Po0.05, from three independent experiments.
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mediated gene expression. This characteristic differs from human
ADAR for HIV-1, for which integrity of the three RNA binding
domains is necessary for HIV-1 LTR activation (Clerzius et al.,
2009).
Overexpression of equine ADAR1 increased EIAV infectivity
The APOBEC3 family of cytidine deaminases plays an important
role in restricting retroviruses by introducing G-to-A hypermutation
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Fig. 2. Equine ADAR1-mediated promotion of EIAV expression is correlated with the LTR and RRE regions. (A) eADAR1 activity is correlated with the LTR region. Either the
eADAR1 expression vector (pADAR1) or the empty control vector (100 ng) was co-transfected with pEIAV-LTR-luc (10 ng) into fetal equine dermal (FED) cells. Luciferase
activity was detected at 24 hpt. The data shown are from three independent experiments. *Po0.05. (B) Overexpression of pADAR1 promoted Env expression. HEK293T cells
were co-transfected with 0.5 μg of the non-codon-optimized Env expression vector pEIAV-Env and different amounts of pADAR1 (0, 3, or 6 μg). At 48 hpt, the cells were
lysed, and the culture supernatants were collected. Env expression was then analyzed by western blot using an equine infectious anemia (EIA)-positive serum.
(C) Overexpression of pADAR1 did not increase the expression of codon-optimized Env. HEK293T cells were co-transfected with 0.1 μg of the codon-optimized Env
expression vector pEIAV-Env-opti and different amounts of pADAR1 (0, 3, or 6 μg). At 48 hpt, the cells were lysed, and the culture supernatants were collected. Env
expression was then analyzed by western blot using an EIA-positive serum. (D) and (E) pADAR1 overexpression did not promote Tat and Rev expression. HEK293T cells were
co-transfected with 0.1 μg of either a Tat or a Rev expression plasmid and increasing doses of pADAR1 (0, 3 or 6 μg). The expression levels of Tat and Rev were examined by
western blot at 48 hpt using an HA antibody to the HA tag fused to Tat and Rev. The images in B, C, D and E show representative results from three independent experiments.
*Po0.05, from three independent experiments.
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of viral genomes, resulting in decreased viral infectivity. APOBEC3
proteins are packaged in HIV-1 particles and restrict replication of
the virus in its subsequent cycle of infection (Lecossier et al., 2003;
Mangeat et al., 2003; Zhang et al., 2003). Here, we have shown that
eADAR1 also upregulates the expression of the EIAV capsid protein
and enhances LTR promoter activity. We therefore examined the
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Fig. 3. The equine ADAR1 RNA-binding domain is required to promote EIAV LTR activity. (A) Schematic representation of the eADAR1 protein showing the sites and domains that
were deleted for the deletion mutant experiments. (B) The deletion mutants were correctly expressed. A western blot of HEK293T cells at 48 hpt is shown. (C) Analysis of LTR
transcriptional activity in response to wild-type eADAR1 or the eADAR1 deletion mutants. The expression levels of the mutants were veriﬁed by western blot. The eADAR1
expression plasmid and eADAR1 deletion mutant expression plasmids (100 ng each) were co-transfected with pEIAV-LTR-luc (10 ng) into FED cells. Luciferase activity was detected
at 24 hpt. (D) Plasmids expressing each of the three functional domains of eADAR1 were constructed. (E) The expression levels of these mutants were examined by western blot
using an anti-HA antibody to the HA tag fused to these eADAR1 fragments. (F) eADAR1 enhanced LTR transcriptional activity when the RNA binding domainwas present. Expression
plasmids for either eADAR1 or each of the three mutants (100 ng) were co-transfected with pEIAV-LTR-luc (10 ng) into FED cells. Luciferase activity was detected at 24 hpt. The
images in B and E show representative results of three independent experiments. *Po0.05, from three independent experiments.
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effect of this equine adenosine deaminase on EIAV infectivity. We
prepared two one-life cycle EIAV-luciferase reporter viruses using
HEK293T cells co-transfected with a plasmid expressing either
eADAR1 (ADAR1) or donkey APOBEC A3Z3 (doA3Z3), a donkey
homolog of human APOBEC3s that restricts EIAV infectivity (unpub-
lished data). These two pseudoviruses, EIAV-ADAR1 and EIAV-
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doA3Z3, were used to infect HEK293T cells at identical doses, which
were standardized using a reverse transcriptase (RT) activity assay
(Fig. 5B). Intracellular luciferase activity was quantiﬁed at 24 hpi. As
shown in Fig. 5A, EIAV-doA3Z3 was poorly infectious, whereas EIAV-
ADAR1 was highly infectious, suggesting that ADAR1 plays a different
role in viral infections than the APOBEC3 proteins.
Discussion
The ability of this adenosine deaminase to promote EIAV
replication can be explained by the following eADAR1 activities.
First, the eADAR1 promotion of EIAV replication is dependent on
RNA binding activity (Figs. 3 and 4). This property may be result
from ADAR1 binding to PKR, which inhibits PKR kinase activity,
resulting in reduced eIF-2a phosphorylation and protein synthesis
(Clerzius et al., 2009, 2011; Pfaller et al., 2011). Indeed, our results
show that the eADAR1-mediated promotion of EIAV gene expres-
sion is associated with the LTR and RRE regions (Fig. 2), which have
been reported to contain RNA secondary structures. The secondary
structure is necessary for PKR activation (Clerzius et al., 2011; Cole,
2007; Sadler and Williams, 2007). However, further studies are
necessary to determine whether the eADAR1 stimulation of EIAV
expression is mediated by the binding of ADAR1 to RNA secondary
structures or by other editing-independent pathways, for instance,
through competitive inhibition of RNA binding to toll-like recep-
tors (TLRs) and retinoic acid inducible-gene I (RIG-I), which are
innate sensors of foreign RNAs and induce antiviral responses (Wu
and Chen, 2014). Second, eADAR1 induces an A-to-G mutation,
which facilitates the adaptation of the virus to a new host. Unlike
the G-to-A hypermutation induced by APOBEC3 proteins (Lecossier
et al., 2003; Mangeat et al., 2003; Zhang et al., 2003), the A-to-G
mutation does not generate stop codons that cause the premature
termination of protein translation. Additionally, in contrast with
APOBEC3G, which is packaged into virions and induces G-to-A
mutations in the genomes of viral progeny, ADAR1 introduces A-to-
G mutations to the genomes of viral progeny, and these mutations
improve viral replication in the next replication cycle. Thus, ADAR1
enhances the ability of a virus to infect a host.
ADAR1 has been identiﬁed as a positive regulator of HIV-1 in
several studies (Clerzius et al., 2009; Doria et al., 2011; Phuphuakrat
et al., 2008). However, a recent publication reported that ADAR1
inhibits HIV-1 replication (Biswas et al., 2012). It is unclear why
these studies obtained contrary results. These inconsistencies may
result from ADAR1 editing activities. Indeed, ADAR1 has dual roles
in virus replication. If ADAR1 edits viral genomes to an appropriate
extent, viral replication is favored. In contrast, when ADAR1 edits
viral genomes massively, virus replication can be hindered. In the
present study, we showed that eADAR1 did not massively edit EIAV
genomes (unpublished data), which may be one of the mechanisms
by which eADAR1 enhances EIAV replication.
In conclusion, we demonstrated that eADAR1 positively regulates
EIAV replication, as evidenced by its ability to enhance LTR-mediated
gene expression, EIAV capsid expression and infectivity. However,
further investigation is necessary to determine whether additional
genomic mutations are required to enhance eADAR1-induced virus
production.
Materials and methods
Plasmids
Equine ADAR1 (eADAR1) cDNA was cloned from mRNA extracted
from eMDMs and expressed using the adenoviral expression vector
pDC315 (Microbix Biosystems, Canada) to generate a protein fused to
an HA tag at the C-terminus (pADAR1). A set of expression vectors
with deletion mutations in the eADAR1 cDNA were constructed using
the primers listed in Table S1. All of the constructed mutants were
conﬁrmed by sequencing. The plasmid pEIAV-Env expressing the
codon-optimized EIAV envelope gene (env) was derived from the
EIAV strain EIAVFDDV3-8 (FDDV3-8) and was kindly provided by Dr. Yi-
Ming Shao (Meng et al., 2011). EIAV-CMV-3-8 is an infectious EIAV
clone derived from FDDV3-8 by substituting the U3 region of the 50
LTRwith the CMV promoter (Wang et al., 2011). The HIV-1 NL4–3 and
SIVmac239 infectious clones were generously provided by Dr. Yong-
Hui Zheng. The EIAV Tat fragment was ampliﬁed from FDDV3-8 and
subcloned into the pEGFP-N1mammalian expression vector (Clontech,
USA) with an HA tag (Tang et al., 2014). The expression plasmids for
the EIAV non-optimized envelope protein (Env) and the nonstructural
protein Rev were constructed as described previously (Yin et al., 2014).
Cells and virus stocks
Primary eMDMs were prepared from equine peripheral blood
mononuclear cells (PBMCs) as described previously (Lin et al.,
2011) and maintained in RPMI 1640 medium containing 60% fetal
bovine serum (FBS). HEK293T and HEK293 cells were maintained
in Dulbecco's Modiﬁed Eagle's Medium containing 10% FBS. A
donkey MDM (dMDM)-adapted pathogenic EIAV strain, EIAVDLV34
(DLV34), was titrated using a reverse transcriptase (RT) assay kit
(Roche, Switzerland) according to the manufacturer's instructions.
EIAV infectivity assay using a luciferase-expressing reporter virus
HEK293T cells were co-transfected with 3.5 μg of either pADAR1
or donkey APOBEC A3Z3 and 1.5 μg of pONY8.1-LUC, 1.5 μg pEIAV-
-p26
- doA3Z3
Supernatant
Lu
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Fig. 5. Equine ADAR1 enhances EIAV infectivity. (A) HEK293T cells were transfected
with 3.5 μg of plasmids expressing either eADAR1 or donkey APOBEC A3Z3
together with DNA from a three-plasmid lentivirus package system (1.5 μg of
pONY8.1-LUC transfer plasmid, 1.5 μg of pEIAV-GagPol packaging plasmid and
0.5 μg of pMD2.0G envelope plasmid), using the calcium phosphate method. The
resulting pseudoviruses were collected and quantiﬁed by measuring the viral RT
activity. HEK293T cells were infected with identical doses of EIAV. Luciferase
activity was detected at 24 hpi. (B) eADAR1 was not packaged into EIAV virions.
The pseudovirus in the supernatant of transfected HEK293T cells was collected, and
the virion quantities were adjusted based on RT activity before being examined by
western blot. An EIA-positive serum was used to detect EIAV p26, and an HA
antibody was used to detect the HA tag fused to eADAR1 and donkey A3Z3. Data
were collected from three independent experiments. The image shown is from a
representative experiment. *Po0.05.
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GagPol and 0.5 μg of pMD2.0 G, using the calcium phosphate
method (Tang et al., 2014; Yin et al., 2014). The VSV-G-packaged
pseudovirus was collected 48 hpt and used to infect HEK293T cells
seeded in 48-well plates. These cells were washed and subjected to
luciferase analysis at 24 hpi.
siRNA knockdown of eADAR1 mRNA in eMDMs
Three ADAR1-speciﬁc siRNAs (siADAR 1-3; see Table S1 for the
sequences) and a scrambled siRNA negative control (siScr) were
synthesized by RiboBio, China. Equine MDMs were seeded in 96-
well plates and cultivated for three days. The cells were then
washed twice with PBS before being transfected with either
eADAR1-speciﬁc or negative control siRNA (diluted to 50 nM in
serum-free media). Knockdown of eADAR1 mRNA was veriﬁed by
reverse transcription PCR.
Transfections and western blotting
Cells were transiently transfected with the plasmids described
above using Lipofectamine 2000 (Invitrogen, USA) according to the
manufacturer's instructions. At 48 hpt, the cells and culture super-
natants were collected separately. The cells were washed once
with PBS and then lysed in RIPA Lysis Buffer containing a protease
inhibitor cocktail (Roche, Switzerland). The supernatants were
centrifuged at 12,000g for 10 min at 4 1C to remove cell debris
and centrifuged again at 20,000g for 2 h at 4 1C to precipitate the
EIAV particles. The proteins in the cell lysates and supernatant
precipitates were separated by SDS-PAGE, transferred to PVDF
membranes (Millipore, Germany) and probed with antibodies.
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